
Ginkgo Bioworks Holdings, Inc.NYSE - DNA
Reports
Search reports
Name | Reporting Date | Filing Date |
---|
2024-09-30 10-Q | 2024-09-30 | 2024-11-12 |
2024-06-30 10-Q | 2024-06-30 | 2024-08-08 |
2024-03-31 10-Q | 2024-03-31 | 2024-05-09 |
2023-12-31 10-K | 2023-12-31 | 2024-02-29 |
2023-09-30 10-Q | 2023-09-30 | 2023-11-08 |
2023-06-30 10-Q | 2023-06-30 | 2023-08-09 |
2023-03-31 10-Q | 2023-03-31 | 2023-05-10 |
2022-12-31 10-K | 2022-12-31 | 2023-03-13 |
2022-09-30 10-Q | 2022-09-30 | 2022-11-14 |
2021-12-31 10-K | 2021-12-31 | 2022-09-01 |
2022-06-30 10-Q | 2022-06-30 | 2022-08-15 |
2022-03-31 10-Q | 2022-03-31 | 2022-05-16 |
2021-12-31 10-K | 2021-12-31 | 2022-03-29 |
2021-09-30 10-Q | 2021-09-30 | 2021-11-15 |
2021-06-30 10-Q | 2021-06-30 | 2021-08-16 |
2021-03-31 10-Q | 2021-03-31 | 2021-05-24 |
1
20 / page
About
Name
Ginkgo Bioworks Holdings, Inc.
Overview
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Show More
CEO
Dr. Jason Kelly Ph.D.
Industry
Biotechnology
Exchange
NYSE
Listing Date
2021-04-19
Address
27 Drydock Avenue, 8th Floor, Boston, MA, 02210, United States
Tel
877-422-5362